Neuropsychiatric‐Led Presentation of Late‐Onset Parkin‐Related Parkinson's Disease
Movement Disorders Clinical Practice, EarlyView.
Sarah Fullam +4 more
wiley +1 more source
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer +16 more
wiley +1 more source
Barriers and Facilitators of the Uptake of Human Immunodeficiency Virus (HIV) Services Among Transgender Women: A Mixed-Methods Study in Delhi, India. [PDF]
Patra S +4 more
europepmc +1 more source
Abstract Background and Objectives Managing substance use disorders (SUDs) is limited by the lack of longitudinal clinical data during active use and recovery. Wearable devices may help address this gap by capturing physiological and behavioral data in real‐world settings.
Alexandra Sas +10 more
wiley +1 more source
A cross sectional seroprevalence study of <i>Bartonella quintana</i> and <i>Bartonella henselae</i> among patients with human immunodeficiency virus (HIV) in Iran. [PDF]
Latifian M +6 more
europepmc +1 more source
Frailty in people aging with human immunodeficiency virus (HIV) infection.
T. Brothers +6 more
semanticscholar +1 more source
Opioid withdrawal syndrome‐associated cognitive impairment: A narrative review
Abstract Background and Objectives Opioid withdrawal syndrome (OWS) comprises a transient constellation of subjective symptoms and objective signs expressed by brain and other organs. Although cognitive impairment is well documented in opioid use and addiction, little is known about cognitive impairment that may specifically accompany OWS.
Faizan Khan +2 more
wiley +1 more source
Human Immunodeficiency Virus (HIV) Knowledge and Stigma: Findings from a Cross-sectional Survey. [PDF]
Myint WW.
europepmc +1 more source
Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy
We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov +43 more
wiley +1 more source

